For Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
|
|
- Shana Little
- 5 years ago
- Views:
Transcription
1 For Adults With Previously Treted Advnced Non-Smll Cell Lung Cncer (NSCLC) individuls depicted re models used for illustrtive purposes only. It cn be overwhelming to lern tht your previously treted dvnced non-smll cell lung cncer (NSCLC) hs come bck or spred fter you hve been through tretments like pltinum-bsed chemotherpy. But even when these options hve been unsuccessful, there my still be nother option for ptients like you (nivolumb). my not work for everyone. Individul results my vry. Who is for? is prescription medicine used to tret type of dvnced lung cncer clled non-smll cell lung cncer. is for dult ptients who: Hve lung cncer tht hs spred or grown; AND Hve tried chemotherpy tht contins pltinum, nd it did not work or is no longer working; AND If their tumor hs n bnorml EGFR or ALK gene, they hve tried n FDA-pproved therpy with these bnorml genes nd it did not work or is no longer working. It is not known if is sfe nd effective in children less thn 18 yers of ge. is medicine tht my tret your lung cncer by working with your immune system. It cn cuse your immune system to ttck norml orgns nd tissues in mny res of your body, nd cn ffect the wy these orgns work. These problems cn sometimes become serious or life-thretening nd cn led to deth. These problems my hppen nytime during tretment or even fter your tretment hs ended. Select Importnt Fcts bout cn cuse problems tht cn sometimes become serious or lifethretening nd cn led to deth. Serious side effects my include lung problems (pneumonitis); intestinl problems (colitis) tht cn led to ters or holes in your intestine; liver problems (heptitis); hormone glnd problems (especilly the thyroid, pituitry, drenl glnds, nd pncres); kidney problems, including nephritis nd kidney filure; skin problems; inflmmtion of the brin (encephlitis); problems in other orgns; nd severe infusion rections. The most common side effects of when used lone include: feeling tired; pin in muscles, bones, nd joints; dirrhe; cough; constiption; bck pin; fever; rsh; itchy skin; nuse; shortness of breth; decresed ppetite; upper respirtory trct infection; nd wekness. is the first nd only immunotherpy the FDA pproved bsed on two phse 3 clinicl trils tht demonstrted longer life for dults with dvnced NSCLC previously treted with pltinum-bsed chemotherpy. If you hve this type of lung cncer, my be n option for you. In clinicl tril of 582 ptients whose dvnced non-squmous NSCLC hd spred or grown fter tretment with pltinum-bsed chemotherpy, 292 were treted with, nd 290 were treted with chemotherpy (docetxel). ws shown to reduce the risk of dying by 27% compred to chemotherpy (docetxel). Hlf of the ptients on were still live t 12.2 months, compred to 9.4 months with chemotherpy (docetxel). Additionlly, ws shown to prtilly or completely shrink tumors in 19% of ptients, compred to 12% with chemotherpy (docetxel). There ws no difference between the two tretments in the length of time tht ptients lived without their tumors worsening. Red bout the second tril in previously treted dvnced squmous NSCLC ptients on the next pge. Is right for me? Tht s converstion you need to hve with your oncologist. But you should know tht is different kind of tretment option tht my work for you. is pproved for dults whose dvnced NSCLC hs spred or grown fter tretment with pltinum-bsed chemotherpy. If your tumor hs n bnorml EGFR or ALK gene, you should hve lso tried n FDA-pproved therpy for tumors with these bnorml genes, nd it did not work or is no longer working. Informtion provided in this brochure is not substitute for tlking with your helthcre professionl. Your helthcre professionl is the best source of informtion bout your disese. Plese see dditionl Importnt Fcts bout, including serious side effects, on pges 5-6 nd ccompnying U.S. Full Prescribing Informtion nd Mediction Guide. Ask your doctor if my be right for you, or visit 1
2 (nivolumb) chnce to live longer is the first nd only immunotherpy the FDA pproved bsed on two phse 3 clinicl trils tht demonstrted longer life for dults with dvnced NSCLC previously treted with pltinum-bsed chemotherpy ADVANCED NON-SQUAMOUS NSCLC TRIAL ADVANCED SQUAMOUS NSCLC TRIAL PATIENTS WERE GIVEN About the Clinicl Tril PATIENTS WERE GIVEN CHEMOTHERAPY (DOCETAXEL) PATIENTS WERE GIVEN About the Clinicl Tril PATIENTS WERE GIVEN CHEMOTHERAPY (DOCETAXEL) Demonstrted Longer Life in Clinicl Tril 27% reduced risk of dying with compred to chemotherpy (docetxel) Hlf the ptients were still live t 12.2 months COMPARED WITH 9.4 months for those who received chemotherpy In the sme study: ws shown to prtilly or completely shrink tumors in 19% of ptients, compred to 12% with chemotherpy (docetxel) There ws no difference between the two tretments in the length of time tht ptients lived without their tumors worsening Demonstrted Longer Life in Clinicl Tril 41% reduced risk of dying with compred to chemotherpy (docetxel) Hlf the ptients were still live t 9.2 months COMPARED WITH 6 months for those who received chemotherpy In the sme study: ws shown to prtilly or completely shrink tumors in 20% of ptients, compred to 9% with chemotherpy (docetxel) The length of time tht hlf of the ptients lived without their tumors worsening ws 3.5 months with nd 2.8 months for chemotherpy (docetxel) will not work for everyone. Individul results my vry. To lern more bout clinicl tril results, visit Wht re the most common side effects of? The most common side effects of include: feeling tired, pin in muscles, bones nd joints, dirrhe, cough, constiption, bck pin, fever, rsh, itchy skin, nuse, shortness of breth, decresed ppetite, upper respirtory trct infection, wekness. These re not ll of the possible side effects of. Tlk to your helthcre tem for more informtion. You cn report ny side effects you experience to the FDA by clling FDA Plese see dditionl Importnt Fcts bout, including serious side effects, on pges 5-6 nd ccompnying U.S. Full Prescribing Informtion nd Mediction Guide. 2
3 How does (nivolumb) work with my immune system? HOW IS DIFFERENT FROM CHEMOTHERAPY? is n immunotherpy tretment tht works with the T cells of your immune system. Lerning more bout the tretment, including how it my work, cn help you hve better converstions with your helthcre tem nd be empowered to mke more-informed tretment decisions. 1 Wht do my T cells do to cncer cells? How does cncer escpe my T cells? Like rdr, your immune system s T cells re lwys serching for threts. Once T cells recognize threts like cncer cells, they become ctive nd ttck them in order to help protect your body. 2 Sometimes, cncer cells re ble to disguise themselves from T cells. If this hppens, cncer cells inctivte T cells so the T cells cnnot ttck. This llows cncer to grow more esily. RECOGNIZE ATTACK Inctive T cell Disguised cncer cells Active T cell Cncer cells HERE S A CLOSER LOOK AT HOW WORKS INSIDE YOUR BODY: 3 How does work inside my body? my help T cells recognize nd ttck cncer cells gin, by blocking cncer s bility to disguise itself. This llows your T cells to be ctive nd to ttck. While doing so, could lso cuse your T cells to ttck helthy cells in your body. Active T cell RECOGNIZE ATTACK Cncer cells Helthy cells cn cuse your T cells to ttck helthy cells contined within orgns nd tissues in mny res of your body nd cn ffect the wy they work. These problems cn sometimes become serious or life-thretening nd cn led to deth, nd my hppen nytime during tretment or even fter your tretment hs ended. Wht re the most serious side effects of? cn cuse problems tht cn sometimes become serious or life-thretening nd cn led to deth. They cn hppen nytime during tretment or even fter tretment hs ended. Serious side effects my include: lung problems (pneumonitis) intestinl problems (colitis) tht cn led to ters or holes in your intestine liver problems (heptitis) hormone glnd problems (especilly the thyroid, pituitry, drenl glnds, nd pncres) kidney problems, including nephritis nd kidney filure skin problems inflmmtion of the brin (encephlitis) problems in other orgns severe infusion rections Plese see dditionl Importnt Fcts bout on pges 5-6 nd ccompnying U.S. Full Prescribing Informtion nd Mediction Guide. 3
4 How is (nivolumb) given? A DOSING SCHEDULE WITH A SINGLE ONE-HOUR INFUSION EVERY TWO WEEKS Week 1 At About Week 9 Receive 1st infusion. Infusions will continue every 2 weeks Receive 1st scn. Continue tretment every 2 weeks s long s it is working nd side effects re tolerble These re generl recommendtions bout tretment timing nd dosing bsed on clinicl tril. Only your doctor cn mke specific recommendtions bout your tretment with. is given through n intrvenous (IV) infusion. The medicine is given directly into the bloodstrem through needle plced in vein by helthcre professionl usully in the rm or hnd. infusions re usully given every 2 weeks. Your doctor will decide how mny tretments you need. You should sty on tretment unless the cncer grows or you hve uncceptble side effects. Your helthcre provider will do blood tests to check you for side effects, nd my tret you with corticosteroid hormone replcement medicines, nd dely or completely stop tretment with if you hve side effects tht re severe. Be sure to tlk to your helthcre tem bout side effects. The infusion tkes 60 minutes, though ctul time in the clinic my vry. Frequent communiction with your helthcre tem is n importnt prt of tretment. Use your 2-week ppointment to let them know how you re feeling nd sk ny questions you my hve. You my lso be ble to tlk with others going through similr sitution. If you miss n ppointment, cll your helthcre provider right wy. Try to schedule your ppointments for the sme dy of the week nd the sme time of dy to mke them esier to remember. It is importnt for you to keep ll ppointments with your helthcre provider. See pge 6 for informtion bout pregnncy, nursing, helth problems, nd other medicines tht you should discuss with your helthcre tem before strting. Questions nd nswers Q Wht types of lung cncer is pproved for? A is pproved for dults with dvnced NSCLC previously treted with pltinum-bsed chemotherpy. NSCLC is the most common type of lung cncer. NSCLC includes squmous nd non-squmous cncers. If your tumor hs n bnorml EGFR or ALK gene, you should hve lso tried n FDA-pproved therpy for tumors with these bnorml genes, nd it did not work or is no longer working. Q A Do people hve to be tested for the PD-L1* biomrker when considering? While does not require PD-L1 biomrker testing, your physicin my still choose to do so to help inform medicl decisions regrding tretment. People were included in the clinicl trils regrdless of their PD-L1 biomrker sttus. Q Where cn I go to get my tretments? A You nd your doctor should discuss the best plce to get your infusions, whether it s your doctor s office, n infusion center, or locl hospitl. Q How do I know if I m responding to? A While undergoing tretment with, your doctor will likely order periodic scns to evlute whether there re ny chnges in the size of your tumors. Sign up for: with You mens just tht: we re here to help you better understnd, whether you or loved one re just considering or lredy hve n prescription. This complimentry progrm includes the following resources. Sign up nd you ll receive: Helpful Informtion for You Get useful tips, tools, nd eductionl mterils tht cn help you lern more bout nd my help support your cre. Support nd Advoccy Groups We cn direct you to orgniztions tht my be helpful for the chllenges you my fce. A Cre Counselor s Close s Your Phone If you re prescribed nd sign up for this dditionl resource, you ll be ble to spek with registered nurse. This personl Cre Counselor cn nswer questions bout tretment nd help you to be more informed prtner with your doctor. Cre Counselors cnnot provide medicl dvice. Your helthcre professionl is the best source of informtion bout your helth. If you d like to sign up for the with You progrm, or if you hve generl questions bout, cll ( ) 8 AM to 8 PM ET, Mondy to Fridy, or visit withyou.com. *Progrmmed deth-lignd 1. Plese see dditionl Importnt Fcts bout, including serious side effects, on pges 5-6 nd ccompnying U.S. Full Prescribing Informtion nd Mediction Guide. 4
5 Importnt Fcts bout (nivolumb) This is summry of importnt informtion tht you need to know bout. Your helthcre tem cn work with you to help nswer ny questions you my hve bout. Keep this informtion in sfe plce, so you cn refer to it before nd during your tretment. Look out for the following icons s you red: Tlk to your helthcre tem Cll helthcre provider right wy Helpful informtion to remember Wht is? is prescription medicine used to tret type of dvnced stge lung cncer clled non-smll cell lung cncer. is for dult ptients who: Hve lung cncer tht hs spred or grown; AND Hve tried chemotherpy tht contins pltinum, nd it did not work or is no longer working; AND If their tumor hs n bnorml EGFR or ALK gene, they hve lso tried n FDA-pproved therpy for tumors with these bnorml genes nd it did not work or is no longer working. It is not known if is sfe nd effective in children less thn 18 yers. is medicine tht my tret your lung cncer by working with your immune system. It cn cuse your immune system to ttck norml orgns nd tissues in mny res of your body, nd cn ffect the wy these orgns work. Wht re the serious side effects of? A serious side effect is side effect tht cn sometimes become life-thretening nd cn led to deth. They cn hppen nytime during tretment or even fter your tretment hs ended. Get medicl help immeditely if you develop ny of these symptoms or they get worse. It my keep these problems from becoming more serious. Your helthcre tem will check you for side effects during tretment with, nd my tret you with corticosteroid or hormone replcement medicines. If you hve serious side effect, your helthcre tem my need to dely or completely stop your tretment. Lung problems (pneumonitis) Things to look out for my include: new or worsening cough chest pin shortness of breth Intestinl problems (colitis) tht cn led to ters or holes in your intestine Things to look out for my include: dirrhe (loose stools) or more bowel movements thn usul blood in your stools or drk, trry, sticky stools severe stomch re (bdomen) pin or tenderness Liver problems (heptitis) Things to look out for my include: yellowing of your skin or the whites of your eyes severe nuse or vomiting pin on the right side of your stomch re (bdomen) drowsiness drk urine (te colored) bleeding or bruising more esily thn norml feeling less hungry thn usul Hormone glnd problems (especilly the thyroid, pituitry, drenl glnds, nd pncres) Things to look out for my include: hedches tht will not go wy or unusul hedches extreme tiredness weight gin or weight loss dizziness or finting chnges in mood or behvior, such s decresed sex drive, irritbility, or forgetfulness hir loss feeling cold constiption voice gets deeper excessive thirst or lots of urine Kidney problems, including nephritis nd kidney filure Things to look out for my include: decrese in the mount of urine blood in your urine swelling in your nkles loss of ppetite Skin problems Things to look out for my include: rsh itching skin blistering ulcers in the mouth or other mucous membrnes Inflmmtion of the brin (encephlitis) Things to look out for my include: hedche fever tiredness or wekness confusion memory problems sleepiness seeing or hering things tht re not relly there (hllucintions) seizures stiff neck Problems in other orgns Things to look out for my include: chnges in eyesight severe or persistent muscle or joint pins severe muscle wekness Plese see dditionl Importnt Fcts bout on pge 6 nd ccompnying U.S. Full Prescribing Informtion nd Mediction Guide. 5
6 Importnt Fcts bout (nivolumb), continued Severe infusion rections Things to look out for my include: chills or shking itching or rsh flushing difficulty brething dizziness fever feeling like pssing out Tlk to your helthcre tem right wy if you get ny of the symptoms of severe infusion rection during or fter n infusion of. Wht should I discuss with my helthcre tem bout pregnncy nd nursing before strting? Tell your helthcre tem if you re pregnnt or pln to become pregnnt. cn hrm your unborn bby. Femles who re ble to become pregnnt should use n effective method of birth control during nd for t lest 5 months fter the lst dose of. Tell your helthcre tem bout birth control methods tht you cn use during this time. Tell your helthcre tem right wy if you become pregnnt during tretment. Tell your helthcre tem if you re brestfeeding or pln to brestfeed. It is not known if psses into your brest milk. Do not brestfeed during tretment. Wht should I discuss with my helthcre tem before strting? Tlk to your helthcre tem bout ll of your helth problems or concerns, including if you: hve immune system problems such s Crohn s disese, ulcertive colitis, or lupus hve hd n orgn trnsplnt hve lung or brething problems hve liver problems hve ny other medicl conditions Wht re the common side effects of? The most common side effects of include: feeling tired rsh pin in muscles, bones, itchy skin nd joints nuse dirrhe shortness of breth cough decresed ppetite constiption upper respirtory trct bck pin infection fever wekness These re not ll of the possible side effects of. Tlk to your helthcre tem for more informtion. You cn report ny side effects you experience to the FDA by clling FDA How will I receive? is prescription medicine tht is given s n intrvenous (IV) infusion by your helthcre tem. An IV infusion is when medicine is given directly into the bloodstrem through needle plced in vein by helthcre professionl - usully in the rm or hnd. 60 minutes intrvenous (IV) infusion time, though ctul time in the clinic my vry. is usully given every 2 weeks. Your doctor will decide how mny tretment cycles you will receive, nd do blood tests to check you for side effects. Cll your doctor right wy to reschedule your ppointment if you miss ny of your ppointments. For more informtion, plese see U.S. Full Prescribing Informtion nd Mediction Guide for, or tlk to your helthcre tem. Tlk to your helthcre tem bout ll of the medicines you re tking, including: prescription medicines over-the-counter medicines vitmins herbl supplements 2017 Bristol-Myers Squibb Compny. rights reserved. nd the relted logo re trdemrks of Bristol-Myers Squibb Compny. 1506US /17 6
7 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (nivolumb) injection, for intrvenous use Initil U.S. Approvl: RECENT MAJOR CHANGES Indictions nd Usge (1) 11/2016 Dosge nd Administrtion (2) 11/2016 Wrnings nd Precutions (5) 10/ INDICATIONS AND USAGE is progrmmed deth receptor-1 (PD-1) blocking ntibody indicted for the tretment of ptients with: BRAF V600 wild-type unresectble or metsttic melnom, s single gent. (1.1) BRAF V600 muttion-positive unresectble or metsttic melnom, s single gent. This indiction is pproved under ccelerted pprovl bsed on progressionfree survivl. Continued pprovl for this indiction my be contingent upon verifiction nd description of clinicl benefit in the confirmtory trils. (1.1) Unresectble or metsttic melnom, in combintion with ipilimumb. This indiction is pproved under ccelerted pprovl bsed on progression-free survivl. Continued pprovl for this indiction my be contingent upon verifiction nd description of clinicl benefit in the confirmtory trils. (1.1) Metsttic non-smll cell lung cncer nd progression on or fter pltinum-bsed chemotherpy. Ptients with EGFR or ALK genomic tumor berrtions should hve disese progression on FDA-pproved therpy for these berrtions prior to receiving. (1.2) Advnced renl cell crcinom who hve received prior nti-ngiogenic therpy. (1.3) Clssicl Hodgkin lymphom tht hs relpsed or progressed fter utologous hemtopoietic stem cell trnsplnttion (HSCT) nd post-trnsplnttion brentuximb vedotin. This indiction is pproved under ccelerted pprovl bsed on overll response rte. Continued pprovl for this indiction my be contingent upon verifiction nd description of clinicl benefit in confirmtory trils. (1.4) Recurrent or metsttic squmous cell crcinom of the hed nd neck with disese progression on or fter pltinum-bsed therpy. (1.5) DOSAGE AND ADMINISTRATION Administer s n intrvenous infusion over 60 minutes. Unresectble or metsttic melnom 240 mg every 2 weeks. (2.1) with ipilimumb: 1 mg/kg, followed by ipilimumb on the sme dy, every 3 weeks for 4 doses, then 240 mg every 2 weeks. (2.1) Metsttic non-smll cell lung cncer 240 mg every 2 weeks. (2.2) Advnced renl cell crcinom 240 mg every 2 weeks. (2.3) Clssicl Hodgkin lymphom 3 mg/kg every 2 weeks. (2.4) Recurrent or metsttic squmous cell crcinom of the hed nd neck 3 mg/kg every 2 weeks. (2.5) FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Unresectble or Metsttic Melnom 1.2 Metsttic Non-Smll Cell Lung Cncer 1.3 Renl Cell Crcinom 1.4 Clssicl Hodgkin Lymphom 1.5 Squmous Cell Crcinom of the Hed nd Neck 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosge for Melnom 2.2 Recommended Dosge for NSCLC 2.3 Recommended Dosge for RCC 2.4 Recommended Dosge for chl 2.5 Recommended Dosge for SCCHN 2.6 Dose Modifictions 2.7 Preprtion nd Administrtion 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Immune-Medited Pneumonitis 5.2 Immune-Medited Colitis 5.3 Immune-Medited Heptitis 5.4 Immune-Medited Endocrinopthies 5.5 Immune-Medited Nephritis nd Renl Dysfunction 5.6 Immune-Medited Skin Adverse Rections 5.7 Immune-Medited Encephlitis 5.8 Other Immune-Medited Adverse Rections 5.9 Infusion Rections 5.10 Complictions of ogeneic HSCT fter 5.11 Embryo-Fetl Toxicity DOSAGE FORMS AND STRENGTHS Injection: 40 mg/4 ml nd 100 mg/10 ml solution in single-dose vil. (3) CONTRAINDICATIONS None. (4) WARNINGS AND PRECAUTIONS Immune-medited pneumonitis: Withhold for moderte nd permnently discontinue for severe or life-thretening pneumonitis. (5.1) Immune-medited colitis: Withhold (nivolumb) when given s single gent for moderte or severe nd permnently discontinue for life-thretening colitis. Withhold when given with ipilimumb for moderte nd permnently discontinue for severe or life-thretening colitis. (5.2) Immune-medited heptitis: Monitor for chnges in liver function. Withhold for moderte nd permnently discontinue for severe or life-thretening trnsminse or totl bilirubin elevtion. (5.3) Immune-medited endocrinopthies: Withhold for moderte or severe nd permnently discontinue for life-thretening hypophysitis. Withhold for moderte nd permnently discontinue for severe or life-thretening drenl insufficiency. Monitor for chnges in thyroid function. Initite thyroid hormone replcement s needed. Monitor for hyperglycemi. Withhold for severe nd permnently discontinue for life-thretening hyperglycemi. (5.4) Immune-medited nephritis nd renl dysfunction: Monitor for chnges in renl function. Withhold for moderte or severe nd permnently discontinue for life-thretening serum cretinine elevtion. (5.5) Immune-medited skin dverse rections: Withhold for severe nd permnently discontinue for life-thretening rsh. (5.6) Immune-medited encephlitis: Monitor for chnges in neurologic function. Withhold for new-onset moderte to severe neurologicl signs or symptoms nd permnently discontinue for immune-medited encephlitis. (5.7) Infusion rections: Discontinue for severe nd life-thretening infusion rections. Interrupt or slow the rte of infusion in ptients with mild or moderte infusion rections. (5.9) Complictions of llogeneic HSCT fter : Monitor for hypercute grft-versushost-disese (GVHD), grde cute GVHD, steroid-requiring febrile syndrome, heptic veno-occlusive disese, nd other immune-medited dverse rections. Trnsplnt-relted mortlity hs occurred. (5.10) Embryo-fetl toxicity: Cn cuse fetl hrm. Advise of potentil risk to fetus nd use of effective contrception. (5.11, 8.1, 8.3) ADVERSE REACTIONS Most common dverse rections ( 20%) in ptients were: s single gent: ftigue, rsh, musculoskeletl pin, pruritus, dirrhe, nuse, stheni, cough, dyspne, constiption, decresed ppetite, bck pin, rthrlgi, upper respirtory trct infection, pyrexi. (6.1) with ipilimumb: ftigue, rsh, dirrhe, nuse, pyrexi, vomiting, nd dyspne. (6.1) To report SUSPECTED ADVERSE REACTIONS, contct Bristol-Myers Squibb t or FDA t FDA-1088 or USE IN SPECIFIC POPULATIONS Lcttion: Discontinue brestfeeding. (8.2) See 17 for PATIENT COUNSELING INFORMATION nd Mediction Guide. Revised: 11/ ADVERSE REACTIONS 6.1 Clinicl Trils Experience 6.2 Immunogenicity 7 DRUG INTERACTIONS 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnncy 8.2 Lcttion 8.3 Femles nd Mles of Reproductive Potentil 8.4 Peditric Use 8.5 Geritric Use 8.6 Renl Impirment 8.7 Heptic Impirment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechnism of Action 12.2 Phrmcodynmics 12.3 Phrmcokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Crcinogenesis, Mutgenesis, Impirment of Fertility 13.2 Animl Toxicology nd/or Phrmcology 14 CLINICAL STUDIES 14.1 Unresectble or Metsttic Melnom 14.2 Metsttic Non-Smll Cell Lung Cncer (NSCLC) 14.3 Renl Cell Crcinom 14.4 Clssicl Hodgkin Lymphom 14.5 Recurrent or Metsttic Squmous Cell Crcinom of the Hed nd Neck (SCCHN) 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing informtion re not listed.
8 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Unresectble or Metsttic Melnom (nivolumb) s single gent is indicted for the tretment of ptients with BRAF V600 wild-type unresectble or metsttic melnom [see Clinicl Studies (14.1)]. s single gent is indicted for the tretment of ptients with BRAF V600 muttion-positive unresectble or metsttic melnom [see Clinicl Studies (14.1)]. This indiction is pproved under ccelerted pprovl bsed on progression-free survivl. Continued pprovl for this indiction my be contingent upon verifiction nd description of clinicl benefit in the confirmtory trils., in combintion with ipilimumb, is indicted for the tretment of ptients with unresectble or metsttic melnom [see Clinicl Studies (14.1)]. This indiction is pproved under ccelerted pprovl bsed on progression-free survivl. Continued pprovl for this indiction my be contingent upon verifiction nd description of clinicl benefit in the confirmtory trils. 1.2 Metsttic Non-Smll Cell Lung Cncer is indicted for the tretment of ptients with metsttic non-smll cell lung cncer (NSCLC) with progression on or fter pltinum-bsed chemotherpy. Ptients with EGFR or ALK genomic tumor berrtions should hve disese progression on FDA-pproved therpy for these berrtions prior to receiving [see Clinicl Studies (14.2)]. 1.3 Renl Cell Crcinom is indicted for the tretment of ptients with dvnced renl cell crcinom (RCC) who hve received prior nti-ngiogenic therpy [see Clinicl Studies (14.3)]. 1.4 Clssicl Hodgkin Lymphom is indicted for the tretment of ptients with clssicl Hodgkin lymphom (chl) tht hs relpsed or progressed fter utologous hemtopoietic stem cell trnsplnttion (HSCT) nd post-trnsplnttion brentuximb vedotin [see Clinicl Studies (14.4)]. This indiction is pproved under ccelerted pprovl bsed on overll response rte. Continued pprovl for this indiction my be contingent upon verifiction nd description of clinicl benefit in confirmtory trils [see Clinicl Studies (14.4)]. 1.5 Squmous Cell Crcinom of the Hed nd Neck is indicted for the tretment of ptients with recurrent or metsttic squmous cell crcinom of the hed nd neck (SCCHN) with disese progression on or fter pltinum-bsed therpy [see Clinicl Studies (14.5)]. 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosge for Melnom The recommended dose of s single gent is 240 mg dministered s n intrvenous infusion over 60 minutes every 2 weeks until disese progression or uncceptble toxicity. The recommended dose of is 1 mg/kg dministered s n intrvenous infusion over 60 minutes, followed by ipilimumb on the sme dy, every 3 weeks for 4 doses [see Clinicl Studies (14.1)]. The recommended subsequent dose of, s single gent, is 240 mg dministered s n intrvenous infusion over 60 minutes every 2 weeks until disese progression or uncceptble toxicity. Review the Full Prescribing Informtion for ipilimumb prior to initition. 2.2 Recommended Dosge for NSCLC The recommended dose of is 240 mg dministered s n intrvenous infusion over 60 minutes every 2 weeks until disese progression or uncceptble toxicity. 2.3 Recommended Dosge for RCC The recommended dose of is 240 mg dministered s n intrvenous infusion over 60 minutes every 2 weeks until disese progression or uncceptble toxicity. 2.4 Recommended Dosge for chl The recommended dose of is 3 mg/kg dministered s n intrvenous infusion over 60 minutes every 2 weeks until disese progression or uncceptble toxicity. 2.5 Recommended Dosge for SCCHN The recommended dose of is 3 mg/kg dministered s n intrvenous infusion over 60 minutes every 2 weeks until disese progression or uncceptble toxicity. 2.6 Dose Modifictions Recommendtions for modifictions re provided in Tble 1. When is dministered in combintion with ipilimumb, if is withheld, ipilimumb should lso be withheld. There re no recommended dose modifictions for hypothyroidism or hyperthyroidism. Interrupt or slow the rte of infusion in ptients with mild or moderte infusion rections. Discontinue in ptients with severe or life-thretening infusion rections. (nivolumb) Tble 1: Recommended Dose Modifictions for Adverse Rection Severity* Dose Modifiction Grde 2 dirrhe or colitis Withhold dose Colitis Grde 3 dirrhe or colitis Withhold dose when dministered s single gent Permnently discontinue when dministered with ipilimumb Grde 4 dirrhe or colitis Permnently discontinue Pneumonitis Grde 2 pneumonitis Withhold dose Grde 3 or 4 pneumonitis Permnently discontinue Asprtte minotrnsferse (AST)/or lnine minotrnsferse (ALT) more thn 3 nd up to 5 times the upper limit of norml or totl Withhold dose Heptitis bilirubin more thn 1.5 nd up to 3 times the upper limit of norml AST or ALT more thn 5 times the upper limit of norml or totl bilirubin more thn 3 times Permnently discontinue the upper limit of norml Hypophysitis Grde 2 or 3 hypophysitis Withhold dose Grde 4 hypophysitis Permnently discontinue Grde 2 drenl insufficiency Withhold dose Adrenl Insufficiency Grde 3 or 4 drenl insufficiency Permnently discontinue Type 1 Dibetes Mellitus Grde 3 hyperglycemi Withhold dose Grde 4 hyperglycemi Permnently discontinue Nephritis nd Renl Dysfunction Skin Encephlitis Other Serum cretinine more thn 1.5 nd up to 6 times the upper limit of norml Serum cretinine more thn 6 times the upper limit of norml Grde 3 rsh or suspected Stevens-Johnson syndrome (SJS) or toxic epiderml necrolysis (TEN) Grde 4 rsh or confirmed SJS or TEN New-onset moderte or severe neurologic signs or symptoms Immune-medited encephlitis Other Grde 3 dverse rection First occurrence Recurrence of sme Grde 3 dverse rections Life-thretening or Grde 4 dverse rection Requirement for 10 mg per dy or greter prednisone or equivlent for more thn 12 weeks Persistent Grde 2 or 3 dverse rections lsting 12 weeks or longer Withhold dose Permnently discontinue Withhold dose Permnently discontinue Withhold dose Permnently discontinue Withhold dose Permnently discontinue Permnently discontinue Permnently discontinue Permnently discontinue * Toxicity ws grded per Ntionl Cncer Institute Common Terminology Criteri for Adverse Events. Version 4.0 (NCI CTCAE v4). Resume tretment when dverse rection returns to Grde 0 or Preprtion nd Administrtion Visully inspect drug product solution for prticulte mtter nd discolortion prior to dministrtion. is cler to oplescent, colorless to ple-yellow solution. Discrd the vil if the solution is cloudy, discolored, or contins extrneous prticulte mtter other thn few trnslucent-to-white, proteinceous prticles. Do not shke the vil. Preprtion Withdrw the required volume of nd trnsfer into n intrvenous continer. Dilute with either 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to prepre n infusion with finl concentrtion rnging from 1 mg/ml to 10 mg/ml.
9 (nivolumb) Mix diluted solution by gentle inversion. Do not shke. Discrd prtilly used vils or empty vils of. Storge of Infusion The product does not contin preservtive. After preprtion, store the infusion either: t room temperture for no more thn 4 hours from the time of preprtion. This includes room temperture storge of the infusion in the IV continer nd time for dministrtion of the infusion or under refrigertion t 2 C to 8 C (36 F to 46 F) for no more thn 24 hours from the time of infusion preprtion. Do not freeze. Administrtion Administer the infusion over 60 minutes through n intrvenous line contining sterile, non-pyrogenic, low protein binding in-line filter (pore size of 0.2 micrometer to 1.2 micrometer). Do not codminister other drugs through the sme intrvenous line. Flush the intrvenous line t end of infusion. When dministered in combintion with ipilimumb, infuse first followed by ipilimumb on the sme dy. Use seprte infusion bgs nd filters for ech infusion. 3 DOSAGE FORMS AND STRENGTHS Injection: 40 mg/4 ml (10 mg/ml) nd 100 mg/10 ml (10 mg/ml) solution in single-dose vil. 4 CONTRAINDICATIONS None. 5 WARNINGS AND PRECAUTIONS 5.1 Immune-Medited Pneumonitis cn cuse immune-medited pneumonitis, defined s requiring use of corticosteroids nd no cler lternte etiology. Ftl cses hve been reported. Monitor ptients for signs with rdiogrphic imging nd for symptoms of pneumonitis. Administer corticosteroids t dose of 1 to 2 mg/kg/dy prednisone equivlents for moderte (Grde 2) or more severe (Grde ) pneumonitis, followed by corticosteroid tper. Permnently discontinue for severe (Grde 3) or life-thretening (Grde 4) pneumonitis nd withhold until resolution for moderte (Grde 2) pneumonitis [see Dosge nd Administrtion (2.6)]. s Single Agent In ptients receiving s single gent, immune-medited pneumonitis occurred in 3.1% (61/1994) of ptients. The medin time to onset of immune-medited pneumonitis ws 3.5 months (rnge: 1 dy to 22.3 months). Immune-medited pneumonitis led to permnent discontinution of in 1.1%, nd withholding of in 1.3% of ptients. Approximtely 89% of ptients with pneumonitis received high-dose corticosteroids (t lest 40 mg prednisone equivlents per dy) for medin durtion of 26 dys (rnge: 1 dy to 6 months). Complete resolution of symptoms following corticosteroid tper occurred in 67% of ptients. Approximtely 8% of ptients hd recurrence of pneumonitis fter re-initition of. with Ipilimumb In ptients receiving with ipilimumb, immune-medited pneumonitis occurred in 6% (25/407) of ptients. The medin time to onset of immune-medited pneumonitis ws 1.6 months (rnge: 24 dys to 10.1 months). Immune-medited pneumonitis led to permnent discontinution or withholding of with ipilimumb in 2.2% nd 3.7% of ptients, respectively. Approximtely 84% of ptients with pneumonitis received high-dose corticosteroids (t lest 40 mg prednisone equivlents per dy) for medin durtion of 30 dys (rnge: 5 dys to 11.8 months). Complete resolution occurred in 68% of ptients. Approximtely 13% of ptients hd recurrence of pneumonitis fter re-initition of with ipilimumb. 5.2 Immune-Medited Colitis cn cuse immune-medited colitis, defined s requiring use of corticosteroids with no cler lternte etiology. Monitor ptients for signs nd symptoms of colitis. Administer corticosteroids t dose of 1 to 2 mg/kg/dy prednisone equivlents followed by corticosteroid tper for severe (Grde 3) or life-thretening (Grde 4) colitis. Administer corticosteroids t dose of 0.5 to 1 mg/kg/dy prednisone equivlents followed by corticosteroid tper for moderte (Grde 2) colitis of more thn 5 dys durtion; if worsening or no improvement occurs despite initition of corticosteroids, increse dose to 1 to 2 mg/kg/dy prednisone equivlents. Withhold for moderte or severe (Grde 2 or 3) colitis. Permnently discontinue for life-thretening (Grde 4) or for recurrent colitis upon re-initition of [see Dosge nd Administrtion (2.6)]. (nivolumb) When dministered in combintion with ipilimumb, withhold nd ipilimumb for moderte colitis (Grde 2). Permnently discontinue nd ipilimumb for severe or life-thretening (Grde 3 or 4) colitis or for recurrent colitis [see Dosge nd Administrtion (2.6)]. s Single Agent In ptients receiving s single gent, immune-medited colitis occurred in 2.9% (58/1994) of ptients; the medin time to onset ws 5.3 months (rnge: 2 dys to 20.9 months). Immune-medited colitis led to permnent discontinution of in 0.7% nd withholding of in 1% of ptients. Approximtely 91% of ptients with colitis received high-dose corticosteroids (t lest 40 mg prednisone equivlents per dy) for medin durtion of 23 dys (rnge: 1 dy to 9.3 months). Four ptients required ddition of infliximb to high-dose corticosteroids. Complete resolution occurred in 74% of ptients. Approximtely 16% of ptients hd recurrence of colitis fter re-initition of. with Ipilimumb In ptients receiving with ipilimumb, immune-medited colitis occurred in 26% (107/407) of ptients including three ftl cses. The medin time to onset of immune-medited colitis ws 1.6 months (rnge: 3 dys to 15.2 months). Immune-medited colitis led to permnent discontinution or withholding of with ipilimumb in 16% nd 7% of ptients, respectively. Approximtely 96% of ptients with colitis received high-dose corticosteroids (t lest 40 mg prednisone equivlents per dy) for medin durtion of 1.1 month (rnge: 1 dy to 12 months). Approximtely 23% of ptients required ddition of infliximb to high-dose corticosteroids. Complete resolution occurred in 75% of ptients. Approximtely 28% of ptients hd recurrence of colitis fter re-initition of with ipilimumb. 5.3 Immune-Medited Heptitis cn cuse immune-medited heptitis, defined s requiring use of corticosteroids nd no cler lternte etiology. Monitor ptients for bnorml liver tests prior to nd periodiclly during tretment. Administer corticosteroids t dose of 1 to 2 mg/kg/dy prednisone equivlents followed by corticosteroid tper for severe (Grde 3) or life-thretening (Grde 4) trnsminse elevtions, with or without concomitnt elevtion in totl bilirubin. Administer corticosteroids t dose of 0.5 to 1 mg/kg/dy prednisone equivlents for moderte (Grde 2) trnsminse elevtions. Withhold for moderte (Grde 2) nd permnently discontinue for severe (Grde 3) or life-thretening (Grde 4) immune-medited heptitis [see Dosge nd Administrtion (2.6)]. s Single Agent In ptients receiving s single gent, immune-medited heptitis occurred in 1.8% (35/1994) of ptients; the medin time to onset ws 3.3 months (rnge: 6 dys to 9 months). Immune-medited heptitis led to permnent discontinution of in 0.7% nd withholding of in 1% of ptients. ptients with heptitis received high-dose corticosteroids (t lest 40 mg prednisone equivlents) for medin durtion of 23 dys (rnge: 1 dy to 2 months). Two ptients required the ddition of mycophenolic cid to high-dose corticosteroids. Complete resolution occurred in 74% of ptients. Approximtely 29% of ptients hd recurrence of heptitis fter re-initition of. with Ipilimumb In ptients receiving with ipilimumb, immune-medited heptitis occurred in 13% (51/407) of ptients; the medin time to onset ws 2.1 months (rnge: 15 dys to 11 months). Immune-medited heptitis led to permnent discontinution or withholding of with ipilimumb in 6% nd 5% of ptients, respectively. Approximtely 92% of ptients with heptitis received high-dose corticosteroids (t lest 40 mg prednisone equivlents per dy) for medin durtion of 1.1 month (rnge: 1 dy to 13.2 months). Complete resolution occurred in 75% of ptients. Approximtely 11% of ptients hd recurrence of heptitis fter re-initition of with ipilimumb. 5.4 Immune-Medited Endocrinopthies Hypophysitis cn cuse immune-medited hypophysitis. Monitor ptients for signs nd symptoms of hypophysitis. Administer hormone replcement s cliniclly indicted nd corticosteroids t dose of 1 mg/kg/dy prednisone equivlents followed by corticosteroid tper for moderte (Grde 2) or greter hypophysitis. Withhold for moderte (Grde 2) or severe (Grde 3). Permnently discontinue for life-thretening (Grde 4) hypophysitis [see Dosge nd Administrtion (2.6)]. In ptients receiving s single gent, hypophysitis occurred in 0.6% (12/1994) of ptients; the medin time to onset ws 4.9 months (rnge: 1.4 to 11 months). Hypophysitis led to permnent discontinution of in 0.1% nd withholding of in 0.2% of ptients. Approximtely 67% of ptients with hypophysitis received hormone replcement therpy nd 33% received high-dose corticosteroids (t lest 40 mg prednisone equivlents per dy) for medin durtion of 14 dys (rnge: 5 to 26 dys). In ptients receiving with ipilimumb, hypophysitis occurred in 9% (36/407) of ptients; the medin time to onset ws 2.7 months (rnge: 27 dys to 5.5 months). Hypophysitis led to permnent discontinution or withholding of with ipilimumb in 1.0% nd 3.9% of ptients, respectively. Approximtely 75% of ptients with hypophysitis received hormone replcement therpy nd 56% received high-dose corticosteroids (t lest 40 mg prednisone equivlents per dy) for medin durtion of 19 dys (rnge: 1 dy to 2.0 months).
10 (nivolumb) Adrenl Insufficiency cn cuse immune-medited drenl insufficiency. Monitor ptients for signs nd symptoms of drenl insufficiency. Administer corticosteroids t dose of 1 to 2 mg/kg/dy prednisone equivlents followed by corticosteroid tper for severe (Grde 3) or life-thretening (Grde 4) drenl insufficiency. Withhold for moderte (Grde 2) nd permnently discontinue for severe (Grde 3) or life-thretening (Grde 4) drenl insufficiency [see Dosge nd Administrtion (2.6)]. In ptients receiving s single gent, drenl insufficiency occurred in 1% (20/1994) of ptients nd the medin time to onset ws 4.3 months (rnge: 15 dys to 21 months). Adrenl insufficiency led to permnent discontinution of in 0.1% nd withholding of in 0.5% of ptients. Approximtely 85% of ptients with drenl insufficiency received hormone replcement therpy nd 25% received high-dose corticosteroids (t lest 40 mg prednisone equivlents per dy) for medin durtion of 11 dys (rnge: 1 dy to 1 month). In ptients receiving with ipilimumb, drenl insufficiency occurred in 5% (21/407) of ptients nd the medin time to onset ws 3.0 months (rnge: 21 dys to 9.4 months). Adrenl insufficiency led to permnent discontinution or withholding of with ipilimumb in 0.5% nd 1.7% of ptients, respectively. Approximtely 57% of ptients with drenl insufficiency received hormone replcement therpy nd 33% received high-dose corticosteroids (t lest 40 mg prednisone equivlents per dy) for medin durtion of 9 dys (rnge: 1 dy to 2.7 months). Hypothyroidism nd Hyperthyroidism cn cuse utoimmune thyroid disorders. Monitor thyroid function prior to nd periodiclly during tretment. Administer hormone-replcement therpy for hypothyroidism. Initite medicl mngement for control of hyperthyroidism. There re no recommended dose djustments of for hypothyroidism or hyperthyroidism. In ptients receiving s single gent, hypothyroidism or thyroiditis resulting in hypothyroidism occurred in 9% (171/1994) of ptients; the medin time to onset ws 2.9 months (rnge: 1 dy to 16.6 months). Approximtely 79% of ptients with hypothyroidism received levothyroxine nd 4% lso required corticosteroids. Resolution occurred in 35% of ptients. Hyperthyroidism occurred in 2.7% (54/1994) of ptients receiving s single gent; the medin time to onset ws 1.5 months (rnge: 1 dy to 14.2 months). Approximtely 26% of ptients with hyperthyroidism received methimzole, 9% received crbimzole, 4% received propylthiourcil, nd 9% received corticosteroids. Resolution occurred in 76% of ptients. In ptients receiving with ipilimumb, hypothyroidism or thyroiditis resulting in hypothyroidism occurred in 22% (89/407) of ptients; the medin time to onset ws 2.1 months (rnge: 1 dy to 10.1 months). Approximtely 73% of ptients with hypothyroidism or thyroiditis received levothyroxine. Resolution occurred in 45% of ptients. Hyperthyroidism occurred in 8% (34/407) of ptients receiving with ipilimumb: the medin time to onset ws 23 dys (rnge: 3 dys to 3.7 months). Approximtely 29% of ptients with hyperthyroidism received methimzole nd 24% received crbimzole. Resolution occurred in 94% of ptients. Type 1 Dibetes Mellitus cn cuse Type 1 dibetes mellitus. Monitor for hyperglycemi. Withhold in cses of severe (Grde 3) hyperglycemi until metbolic control is chieved. Permnently discontinue for life-thretening (Grde 4) hyperglycemi [see Dosge nd Administrtion (2.6)]. In ptients receiving s single gent, dibetes occurred in 0.9% (17/1994) of ptients including two cses of dibetic ketocidosis. The medin time to onset ws 4.4 months (rnge: 15 dys to 22 months). In ptients receiving with ipilimumb, dibetes occurred in 1.5% (6/407) of ptients; the medin time to onset ws 2.5 months (rnge: 1.3 to 4.4 months). with ipilimumb ws withheld in ptient nd permnently discontinued in second ptient who developed dibetes. 5.5 Immune-Medited Nephritis nd Renl Dysfunction cn cuse immune-medited nephritis, defined s renl dysfunction or Grde 2 incresed cretinine, requirement for corticosteroids, nd no cler lternte etiology. Monitor ptients for elevted serum cretinine prior to nd periodiclly during tretment. Administer corticosteroids t dose of 1 to 2 mg/kg/dy prednisone equivlents followed by corticosteroid tper for life-thretening (Grde 4) incresed serum cretinine. Administer corticosteroids t dose of 0.5 to 1 mg/kg/dy prednisone equivlents for moderte (Grde 2) or severe (Grde 3) incresed serum cretinine, if worsening or no improvement occurs, increse dose of corticosteroids to 1 to 2 mg/kg/dy prednisone equivlents. Withhold for moderte (Grde 2) or severe (Grde 3) incresed serum cretinine. Permnently discontinue for life-thretening (Grde 4) incresed serum cretinine. [see Dosge nd Administrtion (2.6) nd Adverse Rections (6.1)]. s Single Agent In ptients receiving s single gent, immune-medited nephritis nd renl dysfunction occurred in 1.2% (23/1994) of ptients; the medin time to onset ws 4.6 months (rnge: 23 dys to 12.3 months). Immune-medited nephritis nd renl dysfunction led to permnent discontinution of in 0.3% nd withholding of in 0.8% of ptients. ptients received high-dose corticosteroids (t lest 40 mg prednisone equivlents per dy) for medin durtion of 21 dys (rnge: 1 dy (nivolumb) to 15.4 months). Complete resolution occurred in 48% of ptients. No ptients hd recurrence of nephritis or renl dysfunction fter re-initition of. with Ipilimumb In ptients receiving with ipilimumb, immune-medited nephritis nd renl dysfunction occurred in 2.2% (9/407) of ptients; the medin time to onset ws 2.7 months (rnge: 9 dys to 7.9 months). Immune-medited nephritis nd renl dysfunction led to permnent discontinution or withholding of with ipilimumb in 0.7% nd 0.5% of ptients, respectively. Approximtely 67% of ptients received high-dose corticosteroids (t lest 40 mg prednisone equivlents per dy) for medin durtion of 13.5 dys (rnge: 1 dy to 1.1 months). Complete resolution occurred in ll ptients. Two ptients resumed with ipilimumb without recurrence of nephritis or renl dysfunction. 5.6 Immune-Medited Skin Adverse Rections cn cuse immune-medited rsh, including Stevens-Johnson syndrome (SJS) nd toxic epiderml necrolysis (TEN), some cses with ftl outcome. For symptoms or signs of SJS or TEN, withhold nd refer the ptient for specilized cre for ssessment nd tretment. If SJS or TEN is confirmed, permnently discontinue [see Dosge nd Administrtion (2.6)]. For immune-medited rsh, dminister corticosteroids t dose of 1 to 2 mg/kg/dy prednisone equivlents followed by corticosteroid tper for severe (Grde 3) or life-thretening (Grde 4) rsh. Withhold for severe (Grde 3) rsh nd permnently discontinue for life-thretening (Grde 4) rsh. s Single Agent In ptients receiving s single gent, immune-medited rsh occurred in 9% (171/1994) of ptients; the medin time to onset ws 2.8 months (rnge: <1 dy to 25.8 months). Immune-medited rsh led to permnent discontinution of in 0.3% nd withholding of in 0.8% of ptients. Approximtely 16% of ptients with rsh received high-dose corticosteroids (t lest 40 mg prednisone equivlents per dy) for medin durtion of 12 dys (rnge: 1 dys to 8.9 months) nd 85% received topicl corticosteroids. Complete resolution occurred in 48% of ptients. Recurrence of rsh occurred in 1.4% of ptients who resumed fter resolution of rsh. with Ipilimumb In ptients receiving with ipilimumb, immune-medited rsh occurred in 22.6% (92/407) of ptients; the medin time to onset ws 18 dys (rnge: 1 dy to 9.7 months). Immune-medited rsh led to permnent discontinution or withholding of with ipilimumb in 0.5% nd 3.9% of ptients, respectively. Approximtely 17% of ptients with rsh received high-dose corticosteroids (t lest 40 mg prednisone equivlents per dy) for medin durtion of 14 dys (rnge: 2 dys to 4.7 months). Complete resolution occurred in 47% of ptients. Approximtely 6% of ptients who resumed nd ipilimumb fter resolution hd recurrence of rsh. 5.7 Immune-Medited Encephlitis cn cuse immune-medited encephlitis with no cler lternte etiology. Evlution of ptients with neurologic symptoms my include, but not be limited to, consulttion with neurologist, brin MRI, nd lumbr puncture. Withhold in ptients with new-onset moderte to severe neurologic signs or symptoms nd evlute to rule out infectious or other cuses of moderte to severe neurologic deteriortion. If other etiologies re ruled out, dminister corticosteroids t dose of 1 to 2 mg/kg/dy prednisone equivlents for ptients with immune-medited encephlitis, followed by corticosteroid tper. Permnently discontinue for immune-medited encephlitis [see Dosge nd Administrtion (2.6)]. s Single Agent In ptients receiving s single gent, encephlitis occurred in 0.2% (3/1994). Ftl limbic encephlitis occurred in one ptient fter 7.2 months of exposure despite discontinution of nd dministrtion of corticosteroids. In the other two ptients encephlitis occurred post-llogeneic HSCT [see Wrnings nd Precutions (5.10)]. with Ipilimumb Encephlitis occurred in one ptient receiving with ipilimumb (0.2%) fter 1.7 months of exposure. 5.8 Other Immune-Medited Adverse Rections cn cuse other cliniclly significnt immune-medited dverse rections. Immune-medited dverse rections my occur fter discontinution of therpy. For ny suspected immune-medited dverse rections, exclude other cuses. Bsed on the severity of the dverse rection, permnently discontinue or withhold, dminister high-dose corticosteroids, nd if pproprite, initite hormone-replcement therpy. Upon improvement to Grde 1 or less, initite corticosteroid tper nd continue to tper over t lest 1 month. Consider restrting fter completion of corticosteroid tper bsed on the severity of the event [see Dosge nd Administrtion (2.6)]. Across clinicl trils of dministered s single gent or in combintion with ipilimumb, the following cliniclly significnt immune-medited dverse rections occurred in less thn 1.0% of ptients receiving : uveitis, iritis, pncretitis, fcil nd bducens nerve presis, demyelintion, polymylgi rheumtic, utoimmune neuropthy, Guillin-Brré syndrome, hypopituitrism, systemic inflmmtory response syndrome, gstritis, duodenitis, srcoidosis, histiocytic necrotizing lymphdenitis (Kikuchi lymphdenitis), myositis, myocrditis, rhbdomyolysis, motor dysfunction, vsculitis, nd mysthenic syndrome.
For Adults with Metastatic Melanoma
For Adults with Metsttic Melnom The + YERVOY Regimen ws shown to reduce the risk of disese progression by nerly 60% compred to YERVOY lone. Hlf of the ptients on + YERVOY were live t 11.5 months without
More informationPatient Monitoring Checklist
Ptient Monitoring Checklist Ptient nme Dte This checklist is intended for nurses or other helthcre professionls (HCPs) to use prior to dosing ech ptient nd t ny follow-up visits or clls with the ptient
More informationYERVOY (ipilimumab) injection, for intravenous use Initial U.S. Approval: 2011
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (ipilimumb) injection, for intrvenous use
More informationIMPORTANT Reminders for Patients. IMPORTANT Information for Doctors/Nurses
Monitor Your Signs nd Symptoms (nivolum) is prescription medicine used in comintion with YERVOY (ipilimum) to tret type of skin cncer clled melnom tht hs spred or cnnot e removed y surgery (dvnced melnom).
More informationImmune-Mediated Adverse Reactions Management Guide
Immune-Medited Adverse Rections Mngement Guide INDICATIONS AND USAGE YERVOY (ipilimumb) is indicted for: Tretment of unresectble or metsttic melnom in dults nd peditric ptients (12 yers nd older) Adjuvnt
More informationFirst-line and Maintenance Treatment with ALIMTA therapy for advanced nonsquamous non-small cell lung cancer (NSCLC)
YOUR LIFE. First-line nd Mintennce Tretment with ALIMTA therpy for dvnced nonsqumous non-smll cell lung cncer (NSCLC) ALIMTA is pproved by the FDA in combintion with cispltin (nother chemotherpy drug)
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 10/2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (ipilimumb) injection, for intrvenous use
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 01/2019
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed for injection),
More informationEfficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationDOSAGE FORMS AND STRENGTHS HIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed disodium)
More informationRevised: 6/2018 History of severe hypersensitivity reaction to pemetrexed. (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------ WARNINGS AND PRECAUTIONS ----------------------- These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively.
More informationPNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationStart ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4
F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed for injection),
More informationSEIZURES AND EPILEPSY
SEIZURES AND EPILEPSY CONTENT CREATED BY Lern more t www.helth.hrvrd.edu TALK WITH YOUR DOCTOR Tble of Contents WHAT IS A SEIZURE? 4 WHAT IS EPILEPSY? 6 TESTING 7 TREATMENT OPTIONS 9 ANTI-SEIZURE MEDICATION
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 02/2011 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use GEMZAR sfely nd effectively. See full prescribing informtion for GEMZAR. GEMZAR (gemcitbine for injection)
More informationGiving appropriate patients another chance to fight OPDIVO
For dmmr/msi-h Colorectal Cancer (CRC) All individuals depicted are models used for illustrative purposes only. Who is OPDIVO for? OPDIVO is a prescription medicine used to treat colorectal cancer (a type
More informationUnderstanding your treatment and the side effects you may experience
Understanding your treatment and the side effects you may experience What does treat? is a prescription medicine used in combination with YERVOY to treat a type of skin cancer called melanoma that has
More informationULTOMIRIS is administered once every 8 weeks a
(rvulizumb-cwvz) for the tretment of dult ptients with proxysml nocturnl hemoglobinuri (PNH) is dministered once every 8 weeks PATIENTS STARTING WITH NO PRIOR TREATMENT FOR PNH THE RECOMMENDED DOSING REGIMEN
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationXII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV
XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not inlude ll the informtion needed to use sfely nd effetively. See full presriing informtion for. (nivolum) injetion, for intrvenous use Initil
More informationXALKORI (crizotinib) Is Available Through Specialty Pharmacies
XALKORI (crizotinib) Is Avilble Through Specilty Phrmcies Specilty Phrmcy Ordering Process The Provider s Office Submits XALKORI prescriptions to the specilty phrmcy vi: Phone Fx Internet Submits ny supporting
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationWeight-Based Dosage Regimen: (2.1) Body Weight Range (kg) Loading Dose (mg) Maintenance Dose (mg) greater or equal to 40 to less than 60 2,400 3,000
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (rvulizumb-cwvz) injection, for intrvenous
More informationAdverse Events Grading Card
Adverse Events Grding Crd Common Terminology Criteri for Adverse Events* In clinicl studies, 2 of the most common dverse events reported with ALAVEN were peripherl neuropthy nd neutropeni. 1 With this
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescriing informtion for ALIMTA. ALIMTA (pemetrexed for injection)
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OPDIVO safely and effectively. See full prescribing information for OPDIVO. OPDIVO (nivolumab) injection,
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More information2.3. with type 1 diabetes <3 years of age. (8.4)
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use HUMALOG sfely nd effectively. See full prescribing informtion for HUMALOG. HUMALOG (insulin lispro
More informationTarget: 10 mg/day within several days Schizophrenia in adolescents (2.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 09/2017 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use Gemzr sfely nd effectively. See full prescriing informtion for Gemzr. GEMZAR (gemcitine for injection),
More informationThe RUTHERFORD-2 trial in heterozygous FH: Results and implications
The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of
More informationDOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.
DOSING GUIDE For patients with unresectable Stage III NSCLC following concurrent CRT For patients with locally advanced or metastatic UC previously treated with platinum-based therapy Enable the immune
More informationGemmis Injection 38 mg/ml
Gemmis Injection 8 mg/ml Gemcitbine (Gemcitbine HCl) is nucleoside nlogue tht exhibits nti-tumor ctivity. The empiricl formul for Gemcitbine HCl is C 9H 11F 2N O.HCl. It hs moleculr weight of 299.66. Gemcitbine
More informationDiscussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor
Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor TECENTRIQ DISCUSSION SUPPORT What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: A type of bladder
More informationHERCEPTIN (trastuzumab) Intravenous Infusion Initial U.S. Approval: 1998
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescriing informtion for. HERCEPTIN (trstuzum) Intrvenous Infusion
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling. Revised: 6/2016 FULL PRESCRIBING INFORMATION: CONTENTS*
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use BASAGLAR sfely nd effectively. See full prescribing informtion for BASAGLAR BASAGLAR (insulin glrgine
More informationFor the Patient: ULUAVPMB
For the Patient: ULUAVPMB Other Names: Treatment of Advanced Non-Small Cell Lung Cancer Using Pembrolizumab U = Undesignated (requires special approval) LU = LUng AV = AdVanced PMB = PeMBrolizumab ABOUT
More informationFor the Patient: USMAVPEM
For the Patient: USMAVPEM Other Names: Treatment of Unresectable or Metastatic Melanoma Using Pembrolizumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced PEM = Pembrolizumab
More information1 Indications and Usage
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ERBITUX sfely nd effectively. See full prescriing informtion for ERBITUX. ERBITUX (cetuxim) injection,
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use Herceptin sfely nd effectively. See full prescriing informtion for Herceptin. HERCEPTIN (trstuzum)
More informationFor the Patient: USMAVNIV
For the Patient: USMAVNIV Other Names: Treatment of Unresectable or Metastatic Melanoma Using Nivolumab U = Undesignated (requires special approval) SM = Skin and Melanoma AV = AdVanced NIV = NIVolumab
More informationof comorbid conditions, interventions Diagnosis and treatment, treatment reduction of risk factors for CVD to slow disease progression,
Tble 5.1. NKF Clssifiction of Chronic Kidney Disese nd Clinicl Fetures Stge Description GFR (ml/ min/1.73 m 2 ) U.S. Prevlence, b # Affected (%) Clinicl Fetures Action Pln c At incresed risk for CKD >60
More informationUniversity of Texas Health Science Center, San Antonio, San Antonio, Texas, USA
Lung Cncer Chemotherpy Given Ner the End of Life by Community Oncologists for Advnced Non-Smll Cell Lung Cncer Jose R. Murillo, Jr., Jim Koeller b,c Methodist Hospitl, Houston, Texs, USA; b University
More informationReducing the Risk. Logic Model
Reducing the Risk Logic Model ETR (Eduction, Trining nd Reserch) is nonprofit orgniztion committed to providing science-bsed innovtive solutions in helth nd eduction designed to chieve trnsformtive chnge
More informationPROFILE OF A PATIENT WITH mbc with visceral metastases
Ptient P.V. PRFILE F A PATIENT WIT mbc with viscerl metstses Indiction Metsttic Brest Cncer ALAVEN (eribulin mesylte) Injection is indicted for the tretment of ptients with metsttic brest cncer (mbc) who
More informationDOSAGE FORMS AND STRENGTHS. Injection: 6 mg single-dose vial. (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use SUMATRIPTAN SUCCINATE INJECTION sfely nd effectively. See full prescribing informtion for SUMATRIPTAN
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationINVEGA SUSTENNA (paliperidone palmitate) extended-release injectable
(pliperidone plmitte) extended-relese injectble suspension, for intrmusculr use HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively.
More informationMaximize Your Genetic Return. Find your Genetic Solution with Boviteq West
Mximize Your Genetic Return. Find your Genetic Solution with Boviteq West Boviteq West is comprehensive reproductive solutions provider, imed t finding the right genetic solution for every niml nd every
More informationSeasonal influenza vaccination programme country profile: Ireland
Sesonl influenz vccintion progrmme country profile: Irelnd 2012 13 Seson Bckground informtion Influenz immunistion policy nd generl fcts bout Irelnd Volume indices of GDP per cpit in 2011 nd 2013 (EU-
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion Read this carefully before you start
More informationBilling and Coding Guide. Hospital Outpatient Department
illing nd oding Guide Hospitl Outptient Deprtment overge, coding, nd pyment in the hospitl outptient deprtment ONPTTRO (ptisirn) received US Food nd Drug dministrtion (FD) pprovl on 10 ug 2018, nd is indicted
More informationRecommended Dosage Regimen for AVYCAZ (ceftazidime and avibactam) b. AVYCAZ 1.25 grams (ceftazidime 1 gram and avibactam 0.25 grams) every 8 hours
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use AVYCAZ sfely nd effectively. See full prescribing informtion for AVYCAZ. AVYCAZ (ceftzidime nd vibctm)
More informationClinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationClinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer
Clinicl Evidence for Second- nd Third-Line Tretment Options in Advnced Non-Smll Cell Lung Cncer Filippo de Mrinis, Frncesco Grossi b Thorcic Oncology Unit I, Deprtment of Lung Diseses, Sn Cmillo nd Forlnini
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion, 20 mg/ml Professed Standard Antineoplastic
More informationYOUR GUIDE TO TECENTRIQ (atezolizumab) non-small cell lung cancer (NSCLC)
YOUR GUIDE TO TECENTRIQ (atezolizumab) For previouslytreated advanced non-small cell lung cancer (NSCLC) ABOUT THIS BOOKLET This booklet is for people with advanced non-small cell lung cancer (NSCLC) who
More informationMecadox. Improves pig performance in a wide range of health and growing conditions. (Carbadox) Talk With a Phibro Expert:
SWINE (Crbdox) Improves pig performnce in wide rnge of helth nd growing conditions The Advntge Over the yers, medicted feed dditive hs proven to be cost-effective mngement tool for improving pig performnce
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More information10-15 mg/day 15 mg/day 30 mg/day. 2-5 mg/day 5-10 mg/day 15 mg/day. 2 mg/day 5-10 mg/day 15 mg/day. 30 mg/day injected IM
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ABILIFY sfely nd effectively. See full prescribing informtion for ABILIFY. Tblets ABILIFY DISCMELT
More informationShort-term therapy with lasting relief 2
# 1 PRESCRIBED MEDICATION APPROVED FOR IBS-D 1 * Short-term therpy with lsting relief 2 provided up to 6 months of symptom relief with 2-week tretment 2 Rnge of 6 to 24 weeks; medin of 10 weeks. Convenient
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationEfficacy of Sonidegib in Patients With Metastatic BCC (mbcc)
AAD 216 eposter 3368 Efficcy of Sonidegib in Ptients With Metsttic BCC (mbcc) Colin Morton, 1 Michel Migden, 2 Tingting Yi, 3 Mnish Mone, 3 Dlil Sellmi, 3 Reinhrd Dummer 4 1 Stirling Community Hospitl,
More informationBright Futures Medical Screening Reference Table 2 to 5 Day (First Week) Visit
Bright Futures Medicl Reference Tle 2 to 5 Dy (First Week) Visit Universl Action Metolic nd Verify documenttion of neworn metolic screening results, pproprite rescreening, nd needed follow-up. Document
More information58 % 50 % REDUCTION IN RISK OF OVERT HE RECURRENCE 1
FOR ADULT PATIENTS WITH OVERT HEPATIC ENCEPHALOPATHY (HE) significntly reduced the risk of overt HE recurrence nd HE-relted hospitliztions 1 58 % 50 % REDUCTION IN RISK OF OVERT HE RECURRENCE 1 REDUCTION
More informationSummary of Package Insert 1
Summry of Pckge Insert 1 For Sttes with Non-Published Policies Indictions Non-infected prtil nd full-thickness skin ulcers due to VSU 2 of greter thn 1 month durtion nd which hve not dequtely responded
More informationSponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept)
These results re supplied for informtionl purposes only. Prescribing decisions should be mde bsed on the pproved pckge insert in the country of prescription. Sponsor / Compny: Snofi Drug substnce(s): AVE0005
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Anaconda- Deer Lodge County. Public Health and Safety Division
Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12
More informationCommunity. Profile Lewis & Clark County. Public Health and Safety Division
Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Missoula County. Public Health and Safety Division
Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationSTEPS SIMPLE TO INTRODUCE ONCE-DAILY THERAPY TO YOUR ADULT PATIENTS WITH TYPE 2 DIABETES START THE CONVERSATION WITH LOOK INSIDE TO FIND OUT HOW
START THE CONVERSATION WITH SIMPLE STEPS TO INTRODUCE ONCE-DAILY THERAPY TO YOUR ADULT PATIENTS WITH TYPE 2 DIABETES LOOK INSIDE TO FIND OUT HOW Indiction nd Limittions of Use Victoz (lirglutide) injection
More informationImportant safety information to minimise the risk of immune-related adverse reactions
Your Guide to KEYTRUDA (pembrolizumab) Important safety information to minimise the risk of immune-related adverse reactions Information for Patients This medicine is subject to additional monitoring.
More informationAmyvid (Florbetapir F 18 Injection) Reader Training
Amyvid (Florbetpir F 18 Injection) Reder Trining Imging Report (Negtive Templte) EXAMINATION: Brin Amyloid PET/CT IMAGING DATE OF STUDY: 01/02/2012 PET ID: 029-004 RADIOPHARMACEUTICAL: 370 MBq (10 mci)
More informationINVEGA SUSTENNA (paliperidone palmitate) extended-release injectable
(pliperidone plmitte) extended-relese injectble suspension, for intrmusculr use HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively.
More informationPrime Enrollees Consumer Watch NHC Patuxent River FY 2016 Defense Health Cost Assessment & Program Evaluation
Prime Enrollees Consumer Wtch NHC Ptuxent River 16 Defense Helth Cost Assessment & Progrm Evlution NHC Ptuxent River: Smple size-1,457 Response rte-1.2% Source: Helth Cre Survey of DoD Beneficiries Inside
More informationDiscussing TECENTRIQ (atezolizumab) with your healthcare team
Discussing TECENTRIQ (atezolizumab) with your healthcare team What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: a type of lung cancer called non-small cell lung cancer (NSCLC). TECENTRIQ
More informationThe potential future of targeted radionuclide therapy: implications for occupational exposure? P. Covens
The potentil future of trgeted rdionuclide therpy: implictions for occuptionl exposure? Introduction: Trgeted Rdionuclide Therpy (TRT) Systemic tretment Molecule lbelled with rdionuclide delivers toxic
More informationWEEK 6 off. WEEK 5 off
SUTENT (sunitini mlte) is indicted for the djuvnt tretment of dult ptients t high risk of recurrent renl cell crcinom (RCC) following nephrectomy. QUICK REFERENCE GUIDE SUTENT Ptient Resources SUTENT In
More informationSPECIALTY PHARMACY ORDERING PROCESS. If option 1 is not applicable, contact Pfizer Patient Support
Specilty Phrmcy Distriution Network for IBRANCE (plocicli), INLYTA (xitini), XALKORI (crizotini), BOSULIF (osutini), nd SUTENT (sunitini mlte) Option Contct the specilty phrmcy directly (See next pge for
More informationSubmitting a Statement of Medical Necessity (SMN) for Humatrope (somatropin for injection)
Sumitting Sttement of Medicl Necessity (SMN) for Humtrope (somtropin for injection) INFORMATION NEEDED FOR FULL SMN FORM SUBMISSION PATIENT INFORMATION: Plese provide Ptient Nme nd Dte of Birth. PRIMARY
More informationCommunity. Profile Carter County. Public Health and Safety Division
Community Helth Profile 2015 Crter County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationReference Slide Deck. Abstract 553 Abstract 554 Abstract 560
Clinicl Spotlight Immunotherpy Advnces for Colorectl Crcinom in 2018: Newly Relesed Dt From the Gstrointestinl Cncers Symposium in Sn Frncisco Reference Slide Deck Abstrct 553 Abstrct 554 Abstrct 560 Mismtch
More informationCLPNA Pressure Ulcers ecourse: Module 5.3 Quiz I page 1
CLPNA Pressure Ulcers ecourse: Module 5.3 Quiz I 1. Clensing is the process of clening nd sterilizing pressure ulcer wound. 2. How often should pressure ulcer wound nd surrounding skin be clensed?. Every
More information5 WAYS VCARE? What is GLAUCOMA. has earned the highest MEDICAID? Are you on. Are you at Risk? Viva Medicare Plus. to Avoid Hospital Readmissions
Enjoy Life! 5 WAYS to Avoid Hospitl Redmissions FOR THE THIRD YEAR IN A ROW, Viv Medicre Plus hs erned the highest MEDICARE STAR RATING GIVEN IN ALABAMA. GLAUCOMA Are you t Risk? Wht is VCARE? Are you
More informationWARNING: RISK OF THYROID C CELL TUMORS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use VICTOZA sfely nd effectively. See full prescriing informtion for VICTOZA. VICTOZA (lirglutide) injection,
More informationOriginal Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:
Fridpur Med. Coll. J. 214;9(2):61-67 Originl Article Nebuliztion by Isotonic Mgnesium Sulphte Solution with Provide Erly nd Better Response s Compred to Conventionl Approch ( Plus Norml Sline) in Acute
More informationTHE CHB TREATMENT GUIDELINE NAVIGATOR REVIEW AN ONLINE INTERACTIVE GUIDE FOR CLINICIANS FEATURING EXPERT AUDIO COMMENTARY
The Americn Assocition for the Study of Liver Diseses () nd the Europen Assocition for the Study of Liver Disese () provide clinicl prctice guidelines for the mngement nd tretment of chronic heptitis B
More informationTR Spitzer 1, CJ Friedman 2, W Bushnell 2, SR Frankel 3, J Raschko 4. Summary:
(2000) 26, 203 210 2000 Mcmilln Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nture.com/bmt Double-blind, rndomized, prllel-group study on the efficcy nd sfety of orl grnisetron nd orl ondnsetron
More informationFor the Patient: USMAVFIPI
For the Patient: USMAVFIPI Other Names: First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced F =
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationManagement and Outcomes of Binge-Eating Disorder in Adults: Current State of the Evidence
Clinicin Summry Mentl Helth Eting Disorders Mngement nd Outcomes of Binge-Eting Disorder in Adults: Current Stte of the Evidence Focus of This Summry This is summry of systemtic review evluting the evidence
More information